Argatroban Use during Pediatric Interventional Cardiac Catheterization

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 1, 2004, Pages 147-149

  Cetta, Frank ^a,b   Graham, Lynn C ^a   Wrona, Laura L ^a   Arruda, M Janine ^a   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Argatroban; Fontan; Heparin induced thrombocytopenia; Interventional catheterization; Pediatrics; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN;

ARTICLE; BALLOON; BLOOD CLOTTING TIME; CASE REPORT; CLINICAL FEATURE; COIL EMBOLIZATION; DEVICE; DISEASE ACTIVITY; DISEASE COURSE; FENESTRATION; FONTAN PROCEDURE; HEART CATHETERIZATION; HEMODYNAMIC MONITORING; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MALE; PRESCHOOL CHILD; PULMONARY VALVE ATRESIA; SAFETY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TRICUSPID VALVE ATRESIA;

ANTITHROMBINS; CHILD; EMBOLIZATION, THERAPEUTIC; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HEART DISEASES; HEPARIN; HUMANS; MALE; PIPECOLIC ACIDS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0346732101     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10720     Document Type: Article

References (19)

1. Porcelli R, Moskowitz BC, Cetta F, Graham LC, Godwin JE, Eidem BW, Prechel MM, Walenga JM. Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation. Tex Heart Inst J 2003;30:58-61.
2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996:101:502-507.
3. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31:1449-1459.
4. Kelton JG. Heparin-induced thrombocytopenia. Haemostasis 1986;16:173-186.
5. Murdoch IA, Beattie RM, Silver DM. Heparin-induced thrombocytopenia in children. Acta Paediatr 1993;82:495-497,
6. Klement D, Rammos S, von Kries R, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression: heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996:155:11-14.
7. Lewis BE, Walenga JM, Hursting MJ. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Cardiovascular Reviews & Reports 2002;23:445-454.
8. Okamoto S, Okunomiya-Hijikata A. Synthetic selective inhibitors of thrombin. Meth Enzymol 1993:222:328-340.
9. Walenga JM, Ahmad S, Hoppensteadt D. et al. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-405.
10. Tran JQ, DiCicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999:39:513-519.
11. Clark RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991:83:1510-1518.
12. Sheth SB, DiCicco RA, Hursting MJ, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001:85:435-440.
13. Inglis AL, Sheth SB, Hursting MJ, Benincosa LJ, DiCicco RA. Investigation of interaction between argatroban and acetaminophen, lidocaine, of digoxin. Am J Health Syst Pharm 2002;59:1258-1266.
14. Hursting MJ, Zehnder JL, Joffrion IL, Becker JL, Knappenberger GD, Schwarz RP. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of the thrmboplastin used. Clin Chem 1999;45:409-412.
15. Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, Bakhos M. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999:25(Suppl 1):61-66.
16. Izawa O, Katsuki M, Komatsu T, Iida S. Pharmacokinetics studies of argatroban (MD-805) in humans: concentrations of argatroban and its metabolites in plasma, urine, and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 1986:14(Suppl 5):251-263.
17. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, for the ARG-911 study investigators. Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
18. Lewis BE, Wallis DE, Zehnder JL, et al., the ARG-911/915/915X investigators. Argatroban re-exposure in patients with heparin-induced thrombocytopenia. Blood 2000;96(Pt 1):52A.
19. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-184.